Expertise in
11
conditions

Dr. Chandra P. Belani

Oncology
The Milton S. Hershey Medical Center
500 University Dr, 
Hershey, PA 
Expertise in
11
conditions
The Milton S. Hershey Medical Center
500 University Dr, 
Hershey, PA 

Overview

Chandra Belani is an Oncologist practicing medicine in Hershey, Pennsylvania.

Dr. Belani is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Pleuropulmonary Blastoma.

He is actively involved in clinical research, co-authoring 103 peer reviewed articles and participating in 18 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in PA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

The Milton S. Hershey Medical Center
500 University Dr, Hershey, PA 17033

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors
An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Paclitaxel, Veliparib
Study Phase: Phase 1
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug
Study Drugs: Adavosertib, Gemcitabine hydrochloride
Study Phase: Phase 2
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 30, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
Enrollment Status: Completed
Publish Date: January 20, 2026
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients With Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients With Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
Enrollment Status: Completed
Publish Date: January 20, 2026
Intervention Type: Drug
Study Drugs: Imprime PGG, MK-3475
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

103 Total Publications

Machine learning integrated extracellular vesicle proteome analysis for early markers of bronchopulmonary dysplasia.
Machine learning integrated extracellular vesicle proteome analysis for early markers of bronchopulmonary dysplasia.
Journal: Function (Oxford, England)
Published: January 19, 2026
Similar Doctors
Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

The Milton S. Hershey Medical Center

500 University Dr, 
Hershey, PA 
 (0.1 miles away)
800-243-1455
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Monika Joshi is an Oncologist practicing medicine in Hershey, Pennsylvania. Dr. Joshi is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Renal Cell Carcinoma (RCC), and Bone Marrow Aspiration.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

The Milton S. Hershey Medical Center

500 University Dr, 
Hershey, PA 
 (0.1 miles away)
717-531-6585
Languages Spoken:
English, Cantonese
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Ma is an Oncologist practicing medicine in Hershey, Pennsylvania. Dr. Ma is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), Squamous Cell Lung Carcinoma, and Bone Marrow Aspiration. Dr. Ma is currently accepting new patients.

Expertise in
21
conditions
Dr. Nelson S. Yee
Hematology | Oncology
Expertise in
21
conditions
Dr. Nelson S. Yee
Hematology | Oncology
Referral may be required

The Milton S. Hershey Medical Center

500 University Dr, 
Hershey, PA 
 (0.1 miles away)
800-243-1455
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nelson Yee is a Hematologist and an Oncologist practicing medicine in Hershey, Pennsylvania. Dr. Yee is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Neuroendocrine Tumor, Familial Pancreatic Cancer, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Chandra P. Belani

How do I make an appointment with Dr. Chandra P. Belani?

You can book an appointment with Dr. Chandra P. Belani by calling their office at 717-531-6585. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Chandra P. Belani a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Chandra P. Belani is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Chandra P. Belani specialize in?

While Dr. Chandra P. Belani is a Oncology, they have specific expertise in Lung Cancer, Small Cell Lung Cancer (SCLC), and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Chandra P. Belani participate in research or clinical trials?

Yes. Dr. Chandra P. Belani has published 103 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Chandra P. Belani's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Chandra P. Belani accept my insurance?

Dr. Chandra P. Belani accepts most major insurance plans, including Cigna and Humana. We recommend calling the office directly at 717-531-6585 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Belani's expertise for a condition
ConditionClose
View All 8 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile